<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039256</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-20190728</org_study_id>
    <nct_id>NCT04039256</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of Percutaneous Ventricular Restoration Using Heartech® Device Preventing Heart Failure Post Myocardial Infarction (The Partical Study)</brief_title>
  <acronym>Partical</acronym>
  <official_title>Efficacy And Safty of Heartech® Left Ventricular Partitioning Device In Treating Heart Failure Post Myocardial Infarction (Phase II Clinical Trial: The Partical Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-group, target-value clinical study. The primary&#xD;
      safety end points are major adverse cardiovascular events (MACCE) 30 days after device&#xD;
      implantation.&#xD;
&#xD;
      The primary efficacy end point is the end of left ventricular systolic volume index (LVESVI)&#xD;
      reduction at 6 month.&#xD;
&#xD;
      The secondary observational end points includes immediate success rate of the procedure,&#xD;
      all-cause mortality, cardiac death, rehospitalization rates and MACCE occurrence rate within&#xD;
      12 month. Besides, left ventricular end systolic volume index (LVESVI) change at 30 days,12&#xD;
      months, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume&#xD;
      index (LVEDVI), 6 minutes walk test, heart function evaluation (NYHA classification) and&#xD;
      quality of life (EQ-5D) at 30 days, 6 months, 12 months will also be evaluated.&#xD;
&#xD;
      After statistical hypothesis and sample size estimation, the sample size of this clinical&#xD;
      trial was 117 cases. All subjects were followed up 30 days, 6 months and 12 months after&#xD;
      implantation of the Heartech® left ventricular partitioning device. All relevant clinical&#xD;
      data were managed by professional data management center, and all relevant clinical data were&#xD;
      statistically analyzed by third-party statistical center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MACCE includes all-cause death, myocardial infarction, stroke and any elective or emergency&#xD;
      cardiac or thoracic aortic surgery or catheter-based interventional therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of MACCE [primary safety]</measure>
    <time_frame>30 days</time_frame>
    <description>major adverse cardiovascular events (MACCE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LVESVi Reduction [primary efficacy]</measure>
    <time_frame>6 month</time_frame>
    <description>left ventricular systolic volume index (LVESVi) reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>immediate</time_frame>
    <description>success rate of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 month</time_frame>
    <description>all-cause mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 month</time_frame>
    <description>cardiac death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>12 month</time_frame>
    <description>rehospitalization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACCE</measure>
    <time_frame>12 month</time_frame>
    <description>MACCE occurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESVi Reduction</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular end systolic volume index (LVESVi) change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEDVi Reduction</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular end-diastolic volume index (LVEDVi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF change</measure>
    <time_frame>12 month</time_frame>
    <description>left ventricular ejection fraction (LVEF) detected by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>12 month</time_frame>
    <description>cardiac function evaluation (NYHA classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk tolerance</measure>
    <time_frame>12 month</time_frame>
    <description>6 minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality</measure>
    <time_frame>12 month</time_frame>
    <description>quality of life (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Efficacy, Safty, Device</condition>
  <arm_group>
    <arm_group_label>PVR implantation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled receive PVR intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous ventricular restoration using heartech® device</intervention_name>
    <description>Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.</description>
    <arm_group_label>PVR implantation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI&lt;40;&#xD;
&#xD;
          -  left ventricular ejection fraction ≤45% and ≥20%;&#xD;
&#xD;
          -  patients with left ventricular end-systolic volume index (ESVI) ≥50mL/m2;&#xD;
&#xD;
          -  transthoracic ultrasound showed contradictory motion of the left ventricle after&#xD;
             myocardial infarction;&#xD;
&#xD;
          -  60 days prior to anterior wall myocardial infarction with ischemic heart failure (NYHA&#xD;
             grade II to &quot;not hospitalized&quot; grade IV);&#xD;
&#xD;
          -  the left ventricle must have the appropriate anatomic structure (size and shape) which&#xD;
             is confirmed by cardiac CT and left ventricular angiography to implant the appropriate&#xD;
             Heartech® device;&#xD;
&#xD;
          -  agree to receive reasonable treatment according to current ACC/AHA and Chinese&#xD;
             guidelines for heart failure diagnosis and treatment;&#xD;
&#xD;
          -  the subjects or their legal representatives are informed of the nature of this study&#xD;
             and agree to participate in all the terms of this study, sign the informed consent&#xD;
             approved by the ethics committee, agree to accept the postoperative treatment plan and&#xD;
             follow-up requirements, and can complete the examination of follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients whose left ventricular anatomy is not suitable for Heartech® occlusal device&#xD;
             implantation;&#xD;
&#xD;
          -  the abnormal ventricular wall movement not contains the anterior wall of the left&#xD;
             ventricle, the apex of the left ventricle and the ventricular septum;&#xD;
&#xD;
          -  patients with thrombosis in the left ventricle;&#xD;
&#xD;
          -  mitral stenosis or regurgitation (tricuspid, aortic or mitral) &gt; 2+ (moderate);&#xD;
&#xD;
          -  recent (within 6 month) cerebrovascular accident (CVA) or transient ischemic attack&#xD;
             (TIA);&#xD;
&#xD;
          -  end-stage renal disease requiring long-term dialysis, episodic sepsis or active phase&#xD;
             endocarditis;&#xD;
&#xD;
          -  life expectancy at admission &lt; 1 year;&#xD;
&#xD;
          -  known allergy to aspirin, heparin, warfarin, Nitinol (alloys of titanium and nickel)&#xD;
             or contraindications, or sensitivity to contrast agents;&#xD;
&#xD;
          -  cardiogenic shock occurred within 72 hours before procedure;&#xD;
&#xD;
          -  pregnancy or planned pregnancy during the study period;&#xD;
&#xD;
          -  participated in clinical trials of other drugs or medical devices during the same&#xD;
             period;&#xD;
&#xD;
          -  the researcher judged that the patient had poor compliance and could not complete the&#xD;
             study as required;&#xD;
&#xD;
          -  other conditions considered unsuitable for participation in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fenghua Ding, MD. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cardiovascular research instittion, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhengbin Zhu, M.D Ph.D.</last_name>
    <phone>021-64370045</phone>
    <phone_ext>673344</phone_ext>
    <email>zzb11561@rhj.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiyan Zhang, MD.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665215</phone_ext>
      <email>zhangruiyan@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Zhengbin Zhu, MD.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665380</phone_ext>
      <email>gemini198306@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruiyan Zhang, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhu Z, Yu J, Xu K, Tang Y, Fang Y, Gu J, Gu S, Ding F, Modine T, Zhang R. First-in-man study of Heartech® percutaneous left ventricular partitioning device for treatment of heart failure postmyocardial infarction. Catheter Cardiovasc Interv. 2019 Nov 15;94(6):845-853. doi: 10.1002/ccd.28366. Epub 2019 Jun 23.</citation>
    <PMID>31231944</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhang Qi, MD</investigator_full_name>
    <investigator_title>Chief of Cardiology Department, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

